Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ATYR1940 Extension in LGMD and FSHD
NCT02836418Phase 2Completed
- Sponsor
- aTyr Pharma
- Start
- Jul 2016
- Primary completion
- Apr 2017
- Modality
- rProtein (Recombinant Protein), Biologic
- Countries
- 3
01
Overview
A Phase 2 trial of Resolaris in limb-girdle muscular dystrophy (LGMD), facioscapulohumeral muscular dystrophy (FSHD), sponsored by aTyr Pharma. Started Jul 2016; status: completed.
02
Drugs
Resolaris
03
Conditions
limb-girdle muscular dystrophy (LGMD)facioscapulohumeral muscular dystrophy (FSHD)
Beyond the preview
Go deeper on NCT02836418.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02836418.